Stockscreener 앱 받기
1.12
2.75%
0.03
전일 마감가:
$1.09
열려 있는:
$1.09
하루 거래량:
30,911
Relative Volume:
0.06
시가총액:
$1.68M
수익:
-
순이익/손실:
$-6.78M
주가수익비율:
-0.0262
EPS:
-42.6996
순현금흐름:
$-4.67M
1주 성능:
-17.04%
1개월 성능:
-54.10%
6개월 성능:
-97.25%
1년 성능:
-98.00%
1일 변동 폭
$1.09
$1.18
1주일 범위
$1.0495
$1.37
52주 변동 폭
$1.0495
$58.00
Clearmind Medicine Inc Stock (CMND) Company Profile
Compare CMND vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
CMND
Clearmind Medicine Inc
|
1.12 | 1.63M | 0 | -6.78M | -4.67M | -42.70 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Clearmind Medicine Inc 주식(CMND)의 최신 뉴스
What technical signals suggest for Clearmind Medicine Inc. stockJuly 2025 Intraday Action & Real-Time Volume Trigger Notifications - mfd.ru
Is Clearmind Medicine Inc. a turnaround storyWeekly Profit Analysis & Weekly Top Performers Watchlists - mfd.ru
Clearmind reports positive safety results in AUD drug trial By Investing.com - Investing.com South Africa
Clearmind reports positive safety data from AUD treatment trial By Investing.com - Investing.com Nigeria
Clearmind reports positive safety results in AUD drug trial - Investing.com Nigeria
Clearmind Medicine announces additional topline positive safety results reinforcing favorable profile of cmnd-100 in ongoing Phase I/Iia clinical trial - marketscreener.com
Clearmind Medicine stock falls after Phase I/IIa trial safety update By Investing.com - Investing.com South Africa
Clearmind Medicine stock falls after Phase I/IIa trial safety update - Investing.com Nigeria
Clearmind reports positive safety data from AUD treatment trial - Investing.com
Clearmind Medicine Announces Additional Positive Safety Topline Data From CMND-100 Study - Nasdaq
Clearmind Medicine Announces Additional Topline Positive Safety Results Reinforcing Favorable Profile of CMND-100 in Ongoing Phase I/IIa Clinical Trial - The Manila Times
Clearmind Medicine Inc. Reports Positive Safety Results from Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder - Quiver Quantitative
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation By Investing.com - Investing.com Nigeria
Clearmind Medicine (CMND) Stock: Partners With Polyrizon to Advance Intranasal MEAI Therapy - parameter.io
Polyrizon climbs on Clearmind Deal - Baystreet.ca
Polyrizon to develop intranasal formulation of Clearmind’s MEAI drug - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal By Investing.com - Investing.com Nigeria
Clearmind partners with Polyrizon to develop intranasal MEAI formulation - Investing.com
Clearmind Medicine stock surges after Polyrizon intranasal delivery deal - Investing.com India
Clearmind Medicine enters development agreement for intranasal formulation of proprietary nonhallucinogenic neuroplastogen MEAI - marketscreener.com
Polyrizon and Clearmind Partner on Intranasal Non-Hallucinogenic Neuroplastogen MEAI - TipRanks
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic Neuroplastogen Formulation - The Manila Times
Clearmind Medicine Enters into Development Agreement to Advance Intranasal Formulation for its Proprietary Non-Hallucinogenic Neuroplastogen MEAI - The Manila Times
Clearmind Medicine Inc. Partners with Polyrizon Ltd. to Develop Innovative Intranasal Formulation for MEAI in CNS Disorders - Quiver Quantitative
Polyrizon Signs an Agreement to Develop Intranasal Proprietary Non-Hallucinogenic ... - Caledonian Record
Biotechs team up on intranasal, non-hallucinogenic addiction therapy - Stock Titan
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ Emerging Therapies Bill to Expand Veteran Access to Innovative Treatments - The Manila Times
Excellent Achievements for Clearmind’s Proprietary MEAI that was Included in U.S. Congress’ ... - Caledonian Record
Breakouts Watch: Is Clearmind Medicine Inc a strong growth stock - baoquankhu1.vn
Aug Retail: Is Clearmind Medicine Inc stock a buy or sellQuarterly Growth Report & Verified Short-Term Plans - baoquankhu1.vn
Aug Macro: Does Varonis Systems Inc have a competitive edgeJobs Report & Real-Time Buy Signal Alerts - baoquankhu1.vn
Clearmind Medicine registers 17M shares for resale linked to $10M convertible note deal - MSN
Clearmind Medicine Inc. Files Annual Report on Form 20-F for the Fiscal Year Ended October 31, 2025 - The Manila Times
Clearmind Medicine Inc. Files Annual Report on Form 20-F for Fiscal Year Ended October 31, 2025 - Quiver Quantitative
Clearmind Medicine: Net loss narrowed, but ongoing losses, no revenue, and funding needs raise going concern risk - TradingView
Will Clearmind Medicine Inc. stock deliver shareholder valueDay Trade & Free Long-Term Investment Growth Plans - bollywoodhelpline.com
Clearmind Medicine regains compliance with NASDAQ minimum bid price rule - MSN
Clearmind Medicine (NASDAQ:CMND) Shares Up 0.4% – What’s Next? - Defense World
Clearmind completes treatment for second cohort in AUD drug trial By Investing.com - Investing.com Nigeria
Clearmind announces completion of treatment for second cohort in CMND-100 trial - TipRanks
Clearmind Completes Treatment In 2nd Cohort Of CMND-100 Phase I/IIa Trial In Alcohol Use Disorder - Nasdaq
Clearmind completes treatment for second cohort in AUD drug trial - Investing.com
Clearmind Medicine IncTopline results from second cohort of CMND-100 expected in coming months - marketscreener.com
Clearmind Medicine Inc. Completes Treatment for Second Cohort in Phase I/IIa Trial of CMND-100 for Alcohol Use Disorder | CMND Stock News - Quiver Quantitative
Clearmind Medicine Announces Successful Completion of Treatment in All Patients of the Second Cohort in Ongoing Phase I/IIa Clinical Trial for CMND-100 - The Manila Times
6 patients finish Clearmind trial testing new alcohol use disorder drug - Stock Titan
Will Clearmind Medicine Inc. outperform tech stocks2025 Trading Recap & Stepwise Trade Signal Implementation - bollywoodhelpline.com
Clearmind Medicine Inc (CMND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.12%
0.87%
자본화:
|
볼륨(24시간):